NCT05701826View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

June 2, 2023

Study Completion Date

June 2, 2023

Conditions
Skeletal Muscle Relaxation
Interventions
DRUG

HRS3797

HRS3797 for injection, low dose

DRUG

HRS3797

HRS3797 for injection, medium dose

DRUG

HRS3797

HRS3797 for injection, high dose

Trial Locations (1)

410013

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY